Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01306591

Bevacizumab for Neovascular Age-related Macular Degeneration

Exudative Age-related Macular Degeneration Clinical Trial

Official title:
Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration

Clinical Trial Summary

Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01306591
Study type Interventional
Source Peking University People's Hospital
Contact
Status Completed
Phase N/A
Start date January 2008
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01608113 - Long-term Follow-up of Subfoveal Neovascular AMD N/A
Completed NCT01404845 - Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation N/A
Completed NCT01213082 - ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Active, not recruiting NCT01961414 - Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Phase 4
Completed NCT01304693 - ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients Phase 1/Phase 2
Completed NCT01810042 - Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Phase 4
Completed NCT04640272 - A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration Phase 2
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01500915 - FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Phase 4
Enrolling by invitation NCT05539235 - Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD Phase 2/Phase 3
Completed NCT02355028 - LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration Phase 2
Unknown status NCT02089503 - Monocentric Retrospective Observational Study on Patients With Macular Degeneration N/A
Completed NCT01796964 - Efficacy and Safety Study of ESBA1008 Versus EYLEA® Phase 2
Completed NCT01127360 - LUCAS (Lucentis Compared to Avastin Study) Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT02328209 - Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration N/A
Completed NCT01849692 - ESBA1008 Microvolume Study Phase 2
Completed NCT01157065 - Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration Phase 2
Completed NCT04138420 - Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab